EHA 2021: fixed-duration therapies and sequencing in CLL

Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment combinations. One emergent strategy is fixed-duration therapy, which combines two or more agents for a set timeframe. Fixed-duration therapy is an appealing option for different reasons, including shorter treatment times and lower costs. Ongoing clinical trials investigating fixed-duration therapy combinations, such as ibrutinib-venetoclax, will help determine the best drug combination as well as the patient populations that will benefit the most. Another increasingly important topic in the CLL field is the optimal treatment selection and sequencing of therapies in the era of targeted therapies.

In this exclusive podcast, Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, and Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, discuss some of the latest updates in CLL treatment presented at the European Hematology Association (EHA) Congress 2021.

The post EHA 2021: fixed-duration therapies and sequencing in CLL appeared first on VJHemOnc.